Related coverage linked through entity extraction aliases.
May 20, 2026
Estrogen-only hormone replacement therapy after risk-reducing bilateral oophorectomy was associated with lower breast cancer risk in women with BRCA1 pathogenic variants. In 919 women followed for an average of 8.8 years, incident breast cancer was lower among HRT users than nonusers.
Feb 15, 2026
Recent research explores plant-based diets' association with breast cancer risk, disparities in care for Black women in Canada, and survival outcomes for young women with breast cancer in Latin America.
Feb 13, 2026
Innovent Biologics has dosed the first participant in its pivotal Phase 3 HeriCare-Breast01 study evaluating IBI354, a HER2-targeted antibody-drug conjugate, as first-line treatment for unresectable locally advanced or metastatic HER2-positive breast cancer.
